New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

See why the ovary − often reduced to its reproductive role − menopause, age and estrogen affect a woman’s health throughout ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

Little is known about what causes ovarian cancer, and there is no way to detect it early yet. About 75% of the time when ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...

Ovarian cancer in particular ... doesn't have great survival,” said one researcher. “Anything we can do to better understand ...